Drug Discovery

#Alzheimer's #Drug development #Drug discovery #FDA #Research

Historic breakthrough in the treatment of Alzheimer’s

The US Food and Drug Administration (FDA) has approved Biogen’s regulatory application for the use of aducanumab in the treatment of Alzheimer’s disease, which removes amyloid from brains. Aducanumab is the first new Alzheimer’s drug in nearly 20 years, and there is reportedly mixed evidence over its efficacy. However, according… Read More

#News

#Biology #Biotechnology #Drug development #Drug discovery #Life sciences #SLAS 2021

Poster award deadlines approaching for SLAS 2021

The deadlines for the Tony B. Academic Award and the Student Poster Award for SLAS Europe 2021 is June 14, a week prior to the conference, which takes place June 23-25 digitally. SLAS’ call for poster abstracts provide opportunities to receive recognition, experience and praise for original research by a… Read More

#News

#Assay #Bioscience #Drug development #Kinetics #Video

Re-energise your kinase discovery programme

Using Promega’s NanoBRET technology, scientists at Aurelia Bioscience have implemented intracellular kinase assays designed to study the interaction of compounds on kinase targets in intact living cells. Advantages of this technique include examination of compound binding to target kinases at physiological ATP concentrations, expression of full-length kinase target… Read More

#Videos

#Covid-19 #Drug discovery

Aspirin does not improve survival for Covid-19 patients

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with Covid-19, who are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly… Read More

#News #Trending News

#Biotechnology #Drug discovery #High throughput screening #Whitepaper

High-throughput screening for small molecule drug discovery

High-throughput screening remains one of the most powerful, unbiased approaches for small molecule drug discovery. In this whitepaper, “Disrupting Drug Discovery From Assay Development to Lead Compound”, SAMDI Tech CSO, Zack Gurard-Levin, discusses the important aspects to consider when choosing the right methodology for drug discovery. The whitepaper covers traditional… Read More

#News

#AI / data analytics / healthtech / informatics #Deep learning #Drug discovery #Pharmaceutical

Opportunities and challenges for AI in drug discovery

By Naheed Kurji, Co-founder and Executive of the Alliance for Artificial Intelligence in Healthcare (AAIH), CEO of Cyclica; and Andreas Windemuth, Ph.D, Chief Science Officer of Cyclica Over the past decade, a new industry has arisen that seeks to apply artificial intelligence (AI), or more aptly machine learning (ML) technologies,… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Trends & Analysis

#Covid-19 #Drug development #Immunology / Virology & Vaccines

Is a needle-free Covid-19 vaccination possible?

University of Queensland scientists have successfully protected mice from the Covid-19 virus by administering a US-developed vaccine candidate with a ‘patch’, rather than a needle. The University of Texas Hexapro vaccine candidate, delivered via the UQ-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP), provided protection against Covid-19 disease with a single,… Read More

#Covid-19 #News #Trending News

#Clinical trial #Diabetes #Drug development #GlobalData #Type 2 diabetes

Eli Lilly’s tirzepatide continues to outperform popular diabetes drugs

Eli Lilly’s tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor agonist (GLP-1RA), recently demonstrated that it was able to not only reduce HbA1c levels in type 2 diabetes (T2D) patients, but also confer weight loss when compared to insulin glargine in the SURPASS-4 trial. Tirzepatide… Read More

#News #Trends & Analysis

#Cancer immunotherapy #Cancer research #Drug development

Are women less susceptible to some skin cancers?

Women may have a stronger immune response to a common form of skin cancer than men, according to early research on mice and human cells. Led by University of Manchester scientists at the Cancer Research UK Manchester Institute, the team publish their findings in Clinical Cancer Research. Men have more… Read More

#Cancer Research #News #Trending News

#Drug delivery #Drug development #Immunology / Virology & Vaccines #mRNA #Vaccines

Samsung Biologics adds mRNA vaccine manufacturing to its services

Samsung Biologics, a CDMO, plans to add mRNA vaccine drug substance (DS) manufacturing capability to its current facility in Songdo, ready for cGMP operations within early 2022. mRNA has been the technology of choice for many Covid-19 vaccines due to its characteristics of safety and fast scalability in manufacturing. “We… Read More

#News

#Antibodies #Drug development #Life sciences

Picking the right custom antibody provider

Selecting the right custom antibody provider for a project is an important decision. It can mean the difference between a breakthrough or failure. It is therefore important where and how antibodies are made. With this infographic, available for free download, you will learn what sets Fortis Life Science’s Bethyl… Read More

#Editor's Choice #News

#Clinical trials #Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Janssen single-dose COVID-19 vaccine approved for use in the UK

Johnson & Johnson has announced topline efficacy and safety data from the Phase III ENSEMBLE clinical trial, demonstrating that the investigational single-dose Covid-19 vaccine in development at Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468… Read More

#Covid-19 #News #Trending News

#Biotechnology #Diagnostics #Drug discovery #Immunology #Immunology / Virology & Vaccines #Pandemic

University of Oxford to launch Pandemic Sciences Centre

The University of Oxford has announced the launch of a new centre of global research collaboration and excellence, the Pandemic Sciences Centre. Its mission will be to ensure that the world is better equipped to create global, and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats. Read More

#News #Trending News

#Drug discovery #Infectious diseases #Life sciences #Research

Millions invested to help life sciences fight infectious disease

The UK’s centre for therapeutics innovation, Medicines Discovery Catapult (MDC), has received a £5 million grant to build a Translational Research Facility in Infectious Disease on its Alderley Park site, as part of the government’s Getting Building Fund programme. Actively seeking collaborations with SMEs, academics and others in infectious disease… Read More

#News

#Clinical trial #Covid-19 #Drug development

Covid-19 patients with sepsis one step closer to life-saving treatment

A clinical trial has begun using a human protein called Annexin A5, which is being studied as a potential therapy for Covid-19 patients with sepsis. Annexin A5 is a protein produced inside the human body with unique anti-coagulation (preventing blood clots) and anti-inflammatory properties that could help in the fight… Read More

#News

#Antibodies #Biotherapeutics #Drug discovery #Drug targets #Genovac

Berkeley Lights: Improving antibody discovery

John Proctor, Senior Vice President of Antibody Therapeutics at Berkeley Lights, and Brian Walters, President/CEO of Genovac Antibody Discovery, talk with DDW’s Megan Thomas about the company’s new Beacon system, which the CRO believes may be the new gold standard in antibody discovery with the potential to up antibody discovery. Read More

#Editor's Choice #Exclusive Content #News